---
title: How risky is a second allogeneic stem cell transplantation?
date: '2024-06-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38918561/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240626181739&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'There is no consensus on second allogeneic stem cell transplantation
  (alloSCT) indications in patients with hematologic malignancies relapsing after
  a first alloSCT. In historic publications, a very high non-relapse mortality (NRM)
  has been described, arguing against performing a second alloSCT. We analysed the
  outcome of 3356 second alloSCTs performed 2011-21 following a hematologic malignancy
  relapse. Outcomes at two years after second alloSCT were: NRM 22%, relapse incidence
  50%, ...'
disable_comments: true
---
There is no consensus on second allogeneic stem cell transplantation (alloSCT) indications in patients with hematologic malignancies relapsing after a first alloSCT. In historic publications, a very high non-relapse mortality (NRM) has been described, arguing against performing a second alloSCT. We analysed the outcome of 3356 second alloSCTs performed 2011-21 following a hematologic malignancy relapse. Outcomes at two years after second alloSCT were: NRM 22%, relapse incidence 50%, ...